dideoxyadenosine

Preferred Label : dideoxyadenosine;

MeSH definition : A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite.;

MeSH synonym : 2',3'-dideoxyadenosine; 2',3' dideoxyadenosine; dda (antiviral);

MeSH CAS label : adenosine, 2',3'-dideoxy-;

MeSH Related Number : 4097-22-7 (Dideoxyadenosine);

Registry Number MeSH : 4097-22-7;

MeSH annotation : an antiviral; inhibits HIV replication;

Codes EINECS : 223-853-2;

Is substance : O;

UNII : 4Q86AH641A;

InChIKey : WVXRAFOPTSTNLL-NKWVEPMBSA-N;

Details

Origin ID

D016048;

UMLS CUI

C0012131;

Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
CISMeF manual mappings
- 2',3'-dideoxyadenosine [Substance BNPC]
Currated CISMeF NLP mapping
- Dideoxyadenosine [NCIt concept]
Pharmacological action(s)
- antimetabolites [MeSH Descriptor]
- antiviral agents [MeSH Descriptor]
Record concept(s)
- dideoxyadenosine [MeSH concept]
Related MeSH Supplementary Concept(s)
- 2',5'-dideoxy-2,5'-difluoroadenosine [MeSH Supplementary Concept]
- 2',5'-dideoxy-2-fluoroadenosine [MeSH Supplementary Concept]
- 2',5'-dideoxy-3'-(4-fluorosulfonylbenzoyl)adenosine [MeSH Supplementary Concept]
- 2',5'-dideoxyadenosine [MeSH Supplementary Concept]
- 2'3'-didehydro-2'3'-dideoxyadenosine [MeSH Supplementary Concept]
- 2,6-diaminopurine 2',3'-dideoxyriboside [MeSH Supplementary Concept]
- 2-bromo-2',3'-dideoxyadenosine [MeSH Supplementary Concept]
- 2-chloro-2',3'-didehydro-2',3'-dideoxyadenosine [MeSH Supplementary Concept]
- 2-chloro-2',3'-dideoxyadenosine [MeSH Supplementary Concept]
- 2-fluoro-2',3'-dideoxyadenosine [MeSH Supplementary Concept]
- 3'-((4-azido-3-iodophenyl)butyryl)-2',5'-dideoxyadenosine [MeSH Supplementary Concept]
- 3'-amino-3',5'-dideoxyadenosine [MeSH Supplementary Concept]
- 3'-azido-2',3'-dideoxyadenosine [MeSH Supplementary Concept]
- 3'-azido-2,6-diaminopurine-2',3'-dideoxyriboside [MeSH Supplementary Concept]
- 3'-fluoro-2,6-diaminopurine-2',3'-dideoxyriboside [MeSH Supplementary Concept]
- 9-(2,3-dideoxy-2,3-difluoro-beta-D-arabinofuranosyl)adenine [MeSH Supplementary Concept]
- 9-(5',6'-dideoxy-beta-ribohex-5'-ynofuranosyl)adenine [MeSH Supplementary Concept]
- 9-(5,6-dibromo-5,6-dideoxyhex-5-enofuranosyl)adenine [MeSH Supplementary Concept]
- 9-(5,6-dideoxy-6-iodo-ribohex-5-enofuranosyl)adenine [MeSH Supplementary Concept]
- 9-(6,6-dibromo-5,6-dideoxyhex-5-enofuranosyl)adenine [MeSH Supplementary Concept]
- 9-(6-bromo-5,6-dideoxy-6-fluorohex-5-enofuranosyl)adenine [MeSH Supplementary Concept]
- abacavir [MeSH Supplementary Concept]
- abacavir 5'-monophosphate [MeSH Supplementary Concept]
- abacavir hydroxyacetate [MeSH Supplementary Concept]
- abacavir, dolutegravir, and lamivudine drug combination [MeSH Supplementary Concept]
- abacavir, lamivudine drug combination [MeSH Supplementary Concept]
- abacavir, lamivudine, and zidovudine drug combination [MeSH Supplementary Concept]
- beta-L-2',3'dideoxyadenosine, bis(S-pivaloyl-2-thioethyl) phosphotriester [MeSH Supplementary Concept]
- lodenosine [MeSH Supplementary Concept]
- ro 24-5098 [MeSH Supplementary Concept]
Semantic type(s)
- Nucleic Acid, Nucleoside, or Nucleotide [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- 2',3'-dideoxyadenosine [Substance BNPC]
- Dideoxyadenosine [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients